Method for screening specific inhibitors of Na+ / H+ antiporter

A screening method for Mrp-type Na+/H+ antiporter inhibitors in E. coli strains addresses the lack of effective inhibitors by comparing growth rates under varying sodium ion concentrations, facilitating targeted drug development for bacterial infections.

JP7593608B2Active Publication Date: 2024-12-03TOYO UNIV EDUCATIONAL FOUND
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
JP2020026178
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2020-02-19
Publication Date
2024-12-03
Estimated Expiration
2040-02-19

AI Technical Summary

Technical Problem

Current methods lack an effective screening process for identifying specific inhibitors of Mrp-type Na+/H+ antiporters, which are potential targets for treating bacterial infections and multidrug resistance, particularly in pathogens like Staphylococcus aureus and Pseudomonas aeruginosa.

Method used

A method involving E. coli strains deficient in endogenous Na+/H+ antiporter genes, with introduced non-E. coli Mrp-type antiporter genes, is cultured under varying sodium ion concentrations with and without test compounds, comparing growth rates to identify compounds that specifically inhibit antiporter function.

Benefits of technology

This method allows for high-sensitivity screening of Mrp-type Na+/H+ antiporter inhibitors, reducing false positives and enabling targeted drug development for bacterial infections.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007593608000002
    Figure 0007593608000002
  • Figure 0007593608000003
    Figure 0007593608000003
  • Figure 0007593608000004
    Figure 0007593608000004
Patent Text Reader

Abstract

To provide an effective screening method for searching for candidates of a compound that specifically inhibits a Na+ / H+ antiporter.SOLUTION: Disclosed is a screening method of a specific inhibitor against a non-E.coli Na+ / H+ antiporter including: (1) culturing a test E.coli in which an endogenous Na+ / H+ antiporter gene is deleted and a non-E.coli Na+ / H+ antiporter gene is introduced in a first sodium ion concentration region of less than 10 mM under the presence of a test compound; (2) culturing the E.coli in a second sodium ion concentration region within the range of 50 to 500 mM under the presence of a test compound; (3) culturing the E.coli in the first sodium ion concentration region under the absence of test compound; and (4) culturing the E.coli in the second sodium ion concentration region under the absence of test compound.SELECTED DRAWING: Figure 3
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure relates to Na + / H + More specifically, the present disclosure relates to a method for screening specific inhibitors of Na antiporters, which are widely present in many eubacteria and archaea. + / H + Antiporters, especially Mrp( M Multiple R Esistance and p H adaptation type Na + / H + The present invention relates to a method for screening for a specific inhibitor of an antiporter. [Background technology]

[0002] Cation / H + Antiporters exist in cell membranes and transport cations and protons (H + , also called hydrogen ions) in opposite directions. For example, Na + / H + In the case of antiporters, H from outside the cell to inside the cell + The transport of sodium ions (Na + ) transport through the cell membrane. + Through this function, antiporters play a variety of physiological roles, including cellular cation tolerance and intracellular pH homeostasis.

[0003] Each species usually has multiple Na + / H + It has antiporter genes and can transport multiple types of Na + / H + They express or have the ability to express antiporter proteins, most of which consist of a single polypeptide or homomultimers thereof, each encoded by a single gene.

[0004] Among them, the unique one is Mrp-type Na + / H + Antiporter. Mrp-type Na + / H + Na antiporters belong to the evolutionarily conserved Mrp family found in many prokaryotes (eubacteria and archaea). + / H + In each prokaryotic species, the protein is characterized by being composed of multiple subunits encoded by multiple genes (usually seven or six) adjacent to each other in an operon. These multiple subunits are hydrophobic polypeptides with different structures. + / H + Antiport activity requires all of these subunits. + / H + Antiporters are also known simply as "Mrp." Past research has demonstrated that Mrp-type Na + / H + It should be noted that antiporters are sometimes called by names other than Mrp. + Instead of or Na + In addition to other types of cations (e.g., K + or Ca 2+ ) are also transported.

[0005] Bacterial infections have been common diseases throughout human history. Thanks to the discovery and invention of various antibiotics, the treatment of bacterial infections has improved significantly. However, even today, serious bacterial infections accompanied by multidrug resistance have become evident in the form of hospital-acquired infections, and have become a social problem. This suggests that the development of new antibiotics that target the sites of action of conventional antibiotics is beginning to show its limits, or at least is no longer able to efficiently deal with the acquisition of multidrug resistance.

[0006] It has been reported that in Staphylococcus aureus and Pseudomonas aeruginosa, which are typical causative bacteria of hospital-acquired infections, deficiency of Mrp can result in reduced infection rate and pathogenicity in mice, an animal model for infectious diseases (Non-Patent Documents 1 and 2). [Prior art documents] [Non-patent literature]

[0007] [Non-Patent Document 1] Journal of Bacteriology, 2005, Vol. 187, No. 15, p. 5242-5248 [Non-Patent Document 2] Journal of Bacteriology, 2018, Vol. 200, Issue 5, e00611-17 Summary of the Invention [Problem to be solved by the invention]

[0008] The present inventors + / H + Antiporters, especially Mrp-type Na + / H + We focused on the possibility that antiporters could be new targets for the treatment or prevention of infectious diseases and multidrug resistance. + / H + There have been no reports of research into screening for inhibitors of Na + / H + The present invention provides an effective screening method for searching for candidate compounds that specifically inhibit an antiporter. [Means for solving the problem]

[0009] The present disclosure encompasses at least the following embodiments. [1] Non-coli Na + / H + A method for screening a specific inhibitor of an antiporter, comprising the steps of: (a-1) Endogenous Na + / H + Antiporter gene is deleted and non-E. coli Na + / H + Cultivating a test E. coli strain into which an antiporter gene has been introduced in the presence of a test compound in a first sodium ion concentration range of less than 10 mM; (a-2) culturing the test E. coli in the presence of the test compound and in a second sodium ion concentration range of 50 to 500 mM; (a-3) culturing the test E. coli in the first sodium ion concentration range in the absence of the test compound; (a-4) culturing the test E. coli in the second sodium ion concentration range in the absence of the test compound; and (b) comparing the growth rate of the test E. coli in (a-1) with the growth rate of the test E. coli in (a-3), and comparing the growth rate of the test E. coli in (a-2) with the growth rate of the test E. coli in (a-4); and performing an assay comprising: method. [2] The non-E. coli Na + / H + Antiporter is Mrp-type Na + / H + The method according to [1], wherein the antiporter is an antiporter. [3] The method according to [1] or [2], wherein the test E. coli is deleted for endogenous nhaA and nhaB genes. [4] The method according to any one of [1] to [3], wherein the test compound is identified as a candidate for a specific inhibitor when there is no growth inhibition in the test E. coli in (a-1) compared to the growth of the test E. coli in (a-3) and there is growth inhibition in the test E. coli in (a-2) compared to the growth of the test E. coli in (a-4). [5] The method according to any one of [1] to [4], wherein the culturing of (a-1) to (a-4) is carried out simultaneously for at least 40 types of test compounds. [Brief description of the drawings]

[0010] [Figure 1A] Figure 1 shows the growth curves of wild-type E. coli (DH5α), the KNabc strain (KNabc / pGEM) with the pGEM7zf(+) vector introduced therein, and the KNabc strain (KNabc / pGEMmnh1) with a vector carrying the mnh1 antiporter gene derived from Staphylococcus aureus introduced therein, in LBK medium supplemented with sodium salts at different concentrations (0 to 600 mM). The growth rate was measured over time from the start of cultivation based on the turbidity (OD600) of the culture medium. [Figure 1B] Figure 1 shows the growth curves of wild-type E. coli (DH5α), the KNabc strain (KNabc / pGEM) with the pGEM7zf(+) vector introduced therein, and the KNabc strain (KNabc / pGEMmnh1) with a vector carrying the mnh1 antiporter gene derived from Staphylococcus aureus introduced therein, in LBK medium supplemented with sodium salts at different concentrations (0 to 600 mM). The growth rate was measured over time from the start of cultivation based on the turbidity (OD600) of the culture medium. [Diagram 2] Figure 2 shows the same growth curves as in Figure 1 for each strain. The arrows indicate the growth curves under the conditions of 300 mM NaCl addition and the absence of test compounds, which were used in the examples. The NaCl addition concentration is shown in M ​​units at the bottom of each panel. [Diagram 3] 3 is an example of a sample arrangement (plate format) of a 96-well microplate that can be used in the screening method according to one embodiment. In this example, 80 types of test compounds are assayed in a total of 80 wells in lanes 2 to 11. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0011] In the present disclosure, non-E. coli Na + / H + The antiporter is a Na ion transporter that is different from the one found in natural Escherichia coli. + / H + It stands for antiporter. Non-E. coli Na + / H + Antiporters are typically derived from prokaryotes other than E. coli (eubacteria or archaea) + / H + In this embodiment, the non-E. coli Na + / H + Antiporters may have orthologs in E. coli, but there are also Na + / H + More preferably, it is an antiporter. + / H + The antiporter may be one that does not exist in native E. coli and has 95% or more amino acid sequence identity over its entire length.

[0012] In one embodiment, the non-E. coli Na + / H + The antiporter is Mrp-type Na + / H + Mrp is an antiporter. It was originally discovered as a protein that could restore alkaline resistance to an alkaline-sensitive mutant of the alkaliphilic bacterium Bacillus halodurans C-125 (J. Bacteriol., 1990, 172, 7282-7283). Native E. coli does not have an Mrp-type Na + / H + E. coli does not have the Mrp-type Na + / H + There are no orthologs of antiporters in the evolutionary lineage. Therefore, by performing assays or screening in the background of E. coli as in the present embodiment, it is possible to detect the Mrp-type Na + / H + It is believed that it is now possible to distinguish specific effects on antiporters with high sensitivity.+ / H + Specific examples of antiporters include Mnh1 in Staphylococcus aureus and Sha in Pseudomonas aeruginosa. The genomes of eukaryotic organisms, including humans, also contain Mrp-type Na + / H + It does not have an antiporter gene.

[0013] The test E. coli used in this embodiment has endogenous Na + / H + The test strain is based on E. coli lacking the antiporter gene (hereinafter, also referred to as the "deficient strain"). The term "endogenous" here means that the gene is inherently possessed by E. coli in its natural state. The test E. coli is at least one of the major Na + / H + It is preferable that the antiporter genes nhaA and nhaB are deleted. It is preferable that the test E. coli is deleted not only of nhaA and nhaB but also of the chaA gene, since this can further improve the sensitivity of screening.

[0014] The term "deficiency of an endogenous gene" refers to a state in which a functional gene product cannot be expressed due to the absence or mutation of a part or all of the endogenous gene. A technique for deleting any endogenous gene of E. coli is within the ordinary skill of a person skilled in the art. For example, the whole or part of the coding region and / or promoter region of the endogenous gene may simply be deleted, or the sequence may be replaced with another foreign sequence (e.g., an antibiotic resistance marker gene sequence). An example of a deletion strain suitable for this embodiment is the KNabc strain. The KNabc strain is derived from the K-12 strain, and the endogenous nhaA, nhaB, and chaA genes are Km, respectively. R ,Cm R , and Erm R It is missing because it has been replaced by a gene.

[0015] The test E. coli was incubated for 1 h at 4°C for 1 h at 20°C. + / H + Instead of lacking the antiporter gene, non-E. coli Na + / H + As mentioned above, it is preferable to use a non-E. coli Na + / H + The antiporter is Mrp-type Na + / H + In this case, the Mrp-type Na + / H + The gene complex encoding all the subunits of the antiporter (typically as an operon) is introduced into E. coli.

[0016] In this embodiment, introducing a non-E. coli gene into E. coli means introducing the nucleic acid of the gene into the E. coli cell so that the E. coli can express the product of the gene. + / H + When the antiporter gene was introduced into the above-mentioned E. coli mutant strain to form a test E. coli, the antiporter gene was expressed in the non-E. coli Na + / H + The gene product of the antiporter is expressed, allowing the endogenous Na + / H + Despite lack of antiporter, Na + In this embodiment, the resistance of non-E. coli Na + / H + It is understood that the antiporter need not necessarily be completely identical in sequence to that found in a naturally occurring or wild-type non- E. coli organism (eg, a non- E. coli prokaryote) and may be a variant relative to the wild-type.

[0017] The test E. coli used in this embodiment is grown in LBK medium containing 200 mM NaCl (Na + The absorbance at 600 nm (OD 600 ) to 0.01 and cultured at 37°C for 16 hours with shaking, the OD was 50% or more or 75% or more higher than that of wild-type E. coli (e.g., DH5α or K-12 strains) cultured under the same conditions.600 It is preferable that the wild-type E. coli can achieve the above. + / H + The antiporter genes are not defective, and the above Na + This is an E. coli strain that can grow normally with or without the addition of an ion source. LBK medium is made by dissolving 10 g of tryptone, 5 g of yeast extract, and 6 g of KCl in water to make 1 L and adjusting the pH to 7.5. + It is a liquid medium that does not contain

[0018] Many specific methods for introducing a non-E. coli gene into E. coli are known to those skilled in the art. For example, it is preferable to introduce the non-E. coli gene into E. coli in the form of a plasmid. It is particularly preferable that the plasmid is a high-copy plasmid capable of replicating 200 or more copies per E. coli cell. One specific example of a suitable plasmid is pGEM available from Promega. The promoter for expression may be a promoter specific to the non-E. coli gene or a heterologous promoter.

[0019] The assay used in the screening method of this embodiment includes culturing a test E. coli in the presence of a test compound (a-1) in a first sodium ion concentration range of less than 10 mM, (a-2) in the presence of the same test compound in a second sodium ion concentration range of 50 to 500 mM, (a-3) in the absence of the test compound in the first sodium ion concentration range, and (a-4) in the absence of the test compound in the second sodium ion concentration range.

[0020] The first sodium ion concentration range is preferably 5 mM or less, more preferably 1 mM or less, and even more preferably substantially 0 mM. +"Containing" means that sodium ions are not intentionally added, and does not take into account trace amounts of sodium ion sources that may inevitably accompany the medium ingredients (e.g., tryptone, yeast extract, water, etc.). Therefore, when the presence or absence of added sodium salts or sodium ions is mentioned in this specification, it should be understood that trace amounts of sodium salts or sodium ions that may inevitably accompany the medium ingredients are not taken into account.

[0021] The second sodium ion concentration range is preferably in the range of 100 to 450 mM, more preferably in the range of 150 to 400 mM, and even more preferably in the range of 200 to 350 mM. Within these concentration ranges, screening can be performed with particularly good sensitivity and high reproducibility. The actual sodium ion concentrations in (a-2) and (a-4) can be made substantially the same (for example, within an error range of 10 mM between them), and the actual sodium ion concentrations in (a-1) and (a-3) can be made substantially the same (for example, within an error range of 5 mM between them).

[0022] The above cultures (a-3) and (a-4) are cultures that provide a reference point for the degree of growth when grown without interference in the absence of the test compound.

[0023] In order to make the comparison easier, it is preferable to make the conditions of the above cultures (a-1) to (a-4) the same except for the sodium salt concentration (sodium ion concentration) and the presence or absence of the test compound. This may mean making the basal medium and culture temperature the same. Those skilled in the art who refer to this disclosure can determine an appropriate basal medium and culture temperature for observing the effect of the sodium ion concentration and the presence or absence of the test compound on the growth (proliferation) of the test E. coli. The basal medium means a medium in which the addition of the sodium salt and the test compound is omitted. The above-mentioned LBK medium is a suitable basal medium. It is considered that the comparison will be most easily made by making the basal medium and culture temperature of the cultures (a-1) to (a-4) the same, making the sodium salt concentration of (a-1) and (a-3) the same, making the sodium salt concentration of (a-2) and (a-4) the same, and making the test compound concentration of (a-1) and (a-2) the same.

[0024] In the cultures of (a-1) to (a-4), particularly between (a-1) and (a-3), and between (a-2) and (a-4), and between (a-1) and (a-2), and between (a-3) and (a-4), the OD was measured without addition of the test compound. 600 When the bacteria were inoculated so that the OD was 0.01 and cultured at 37°C for 16 hours with shaking, the OD 600 It is preferable that the medium composition can support the achievement of OD of 50% or more or 75% or more, respectively, compared with wild-type E. coli (e.g., DH5α strain or K-12 strain) cultured under the same conditions in LBK medium. 600 It is more preferable to have a medium composition that can support the achievement of the above. Such a medium composition usually contains 5 to 200 mM potassium ions (K + ) concentration, preferably a potassium ion concentration of 50 to 100 mM. The pH of the medium is usually 7.0 to 8.0.

[0025] The cultures (a-1) to (a-4) are each preferably carried out at a temperature of 30 to 38° C., more preferably at a temperature of 35 to 37.5° C. The culture temperatures of (a-1) to (a-4) can be aligned within an error range of 1° C.

[0026] The concentration of the test compound in the cultures (a-1) and (a-2) may vary depending on various factors such as the type and potency range of the specific compound that the user intends to screen, but may be, for example, 1 μM to 1 mM, or 20 μM to 100 μM. The concentrations of the test compound in (a-1) and (a-2) may be the same within an error range of 10%.

[0027] The assay used in the method according to the present embodiment includes, as the next step (b), comparing the growth of the test E. coli in (a-1) with that in (a-3), and comparing the growth of the test E. coli in (a-2) with that in (a-4). Through this comparison, it is possible to search for a test compound that reduces the growth of (a-2) compared to (a-4), but does not reduce the growth of (a-1) compared to (a-3), or the reduction is smaller than the above. This system allows the detection of non-E. coli Na + / H + By identifying specific inhibitors of sodium ion resistance dependent on the antiporter, we have identified the mechanism by which non-E. coli Na + / H + Candidate inhibitors specific for antiporter function can be identified.

[0028] To make the comparison easier, it is preferable to compare the growth rates of the cultures (a-1) to (a-4) at the same time after the start of the culture. Therefore, it is preferable to start the cultures (a-1) to (a-4) at the same time under the same conditions. The start of culture is usually understood to mean, in the case of a liquid medium, inoculating the bacterial cells or preculture solution into the main culture solution to start shaking culture, and in the case of a solid medium, inoculating the bacterial cells or preculture solution into the solid medium to start stationary culture.

[0029] For example, it is preferable to compare the growth degrees at 3 to 24 hours, 4 to 20 hours, or 8 to 18 hours after the start of the culture of (a-1) to (a-4). In particular, when the second sodium ion concentration range is 100 mM or less, it may be preferable to compare the growth degrees at 3 to 6 hours or 3 to 16 hours after the start of the culture. When the second sodium ion concentration is 400 mM or more, it may be preferable to compare the growth degrees at 8 to 24 hours or 14 to 24 hours after the start of the culture. The optimal comparison time point is when the non-E. coli NaCl concentration to be screened is 100 mM or less. + / H + Although this may vary depending on the specific type of antiporter, it can be determined appropriately by those skilled in the art. For example, + / H + The OD of the culture in (a-4) was compared to the control culture in which the antiporter was not introduced and the conditions were the same. 600 The above-mentioned comparison of growth degrees can be performed at the point where the value of is 0.2 or more, preferably 0.25 or more, more preferably 0.3 or more, and even more preferably 0.4 or more.

[0030] If there is no growth inhibition in the growth of the test E. coli in (a-1) compared to the growth of the test E. coli in (a-3), and there is growth inhibition in the growth of the test E. coli in (a-2) compared to the growth of the test E. coli in (a-4), the test compound can be identified as a candidate for a specific inhibitor. If there is growth inhibition in (a-2) compared to (a-4) and also in (a-1) compared to (a-3), the test compound can be identified as a candidate for a specific inhibitor. + / H + Since the growth inhibition occurs under conditions that do not require the presence of the antiporter, the test compound is not required to inhibit the growth of non-E. coli Na + / H + It is not a specific inhibitor of the antiporter, but rather appears to inhibit the growth of E. coli through some other mechanism.

[0031] Here, when a liquid medium is used, "no growth inhibition" means that the turbidity of the medium is not 50% or less of the control, and "growth inhibition" means that the turbidity of the medium is 50% or less of the control. The turbidity of the medium reflects the cell density, for example, OD 600 It is understood by those skilled in the art that a relative comparison of turbidity can be made as long as the measurements are performed using the same spectrophotometer under the same conditions. It is also well known to those skilled in the art that the medium turbidity, which is an index of growth (proliferation), is quantified as a value obtained by subtracting the absorbance of the medium itself from the absorbance of the measurement container (cuvette, plate well, etc.).

[0032] In a screening embodiment for searching for inhibitors with higher specificity and / or potency, a test compound may be identified as a candidate specific inhibitor when the turbidity of the medium in (a-1) is 75% or more, more preferably 80% or more, and even more preferably 90% or more compared to the turbidity of the medium in (a-3), and / or the turbidity of the medium in (a-2) is 25% or less, more preferably 20% or less, and even more preferably 10% or less compared to the turbidity of the medium in (a-4).

[0033] In another specific embodiment, test compounds that satisfy the conditions represented by the following formula may be identified as candidate specific inhibitors. [Turbidity of medium in (a-1)] / [Turbidity of medium in (a-3)]×100-[Turbidity of medium in (a-2)] / [Turbidity of medium in (a-4)]×100≧x Here, x is 50, preferably 60, more preferably 70, and even more preferably 80.

[0034] The screening method of this embodiment is preferably carried out using a liquid medium, but an embodiment using a solid medium such as an agar medium is also contemplated. When a solid medium is used, "there is no growth inhibition of the test E. coli in (a-1) compared to the growth of the test E. coli in (a-3)" means that colony formation is observed in both (a-3) and (a-1), and "there is growth inhibition of the test E. coli in (a-2) compared to the growth of the test E. coli in (a-4)" means that colony formation is observed in (a-4) but not in (a-2). The presence or absence of colony formation can be determined with the naked eye according to the conventions in this technical field. The solid medium may be a gel obtained by adding agar to the above-mentioned liquid medium.

[0035] In the screening method of this embodiment, it is understood that the same set of assays (a-1) to (a-4) and (b) is performed for multiple types of test compounds. Preferably, at least 40 types, more preferably at least 80 types of test compounds may be simultaneously cultured (a-1) to (a-4). When a liquid medium is used, the volume of each assay, i.e., the culture of (a-1) to (a-4), is preferably 1 mL or less, more preferably 200 μL or less, and even more preferably 100 μL or less. In this screening method, a multi-well plate, for example a 96-well plate, can be used as a culture vessel and / or a measurement vessel. The cultures of (a-3) and (a-4) do not necessarily have to be performed for the number of test compounds. That is, the cultures of (a-1) and (a-2) are each performed for the number of test compounds to be screened, but the cultures of (a-3) and (a-4), which are comparison objects not containing the test compounds, may each be provided in common for multiple test compounds.

[0036] Embodiments of the present disclosure may be characterized by a low false positive rate.Embodiments of the present disclosure may also be suitable for implementation as high-throughput screening systems, which may be directly applicable to drug discovery research or development.

[0037] Furthermore, since the embodiments of the present disclosure are capable of evaluating and identifying candidate inhibitor compounds using the presence or absence of microbial growth or the level of growth as an indicator, screening can be performed at low cost using relatively simple equipment.

[0038] In the present disclosure, the symbol "~" indicating a numerical range means that the numerical values ​​before and after it are included as the lower and upper limits, respectively. When multiple possible numerical ranges are separately described, such as "A~B" and "C~D", numerical ranges combining one lower limit or upper limit with the other upper limit or lower limit (e.g., "A~D", "C~B", and "B~D") should also be understood as being disclosed in the present specification. In addition, when a combination of a first element and a second element is described, and multiple possible options are described for each of the first element and the second element, all possible combinations of each option of the first element and each option of the second element should be understood as being disclosed in the present specification. EXAMPLES

[0039] Here, we investigated the Mrp-type Na + / H + Here, we describe an example of searching for an antiporter inhibitor. The mrp gene (mnh1) operon derived from Staphylococcus aureus was cloned into a high-copy plasmid vector of Escherichia coli, and the plasmid was introduced into the E. coli KNabc strain by standard methods for transformation. The KNabc strain is the main Na + / H +This is a strain lacking the antiporter, and at pH 7.5, when the NaCl concentration in the medium was increased to about 50 mM, growth began to be clearly delayed, and in the presence of 100 mM NaCl, growth was significantly inhibited, and in the presence of 200 mM NaCl or more, growth was almost completely inhibited. In contrast, wild-type E. coli and the KNabc strain expressing Mrp derived from Staphylococcus aureus can grow even in the presence of NaCl up to 600 mM (Figs. 1 and 2). Figures 1 and 2 show the growth rate as a function of time after the start of main culture, after preculture as described below, inoculation into the main culture solution, and main culture in the presence of different concentrations of NaCl.

[0040] Wild-type E. coli, including the parent strain of KNabc, naturally have Mrp-type Na + / H + This example shows that endogenous Na + / H + Antiporter deficiency and Mrp-type Na + / H + Na in E. coli with antiporters + This demonstrates that changes in resistance can be used to very clearly distinguish inhibitor candidates that exhibit specific inhibitory activity towards Mrps.

[0041] 1. Reagents ·Bacto Tryptone(Difco Laboratories No. 211705) ·Bacto Yeast Extract(Difco Laboratories No. 212750) ·NaCl (special grade, Wako Pure Chemical No. 191-01665) ·KCl (special grade, Wako Pure Chemical No. 161-03541) Potassium hydroxide (special grade, Wako Pure Chemical No. 162-21813)

[0042] 2. Strains and Plasmids Used E. coli KNabc strain (derived from K-12, ΔnhaA::Km R , ΔnhaB::Cm R, ΔchaA::Erm R ) pGEMmnh1 plasmid (the mnh1 operon of S. aureus is cloned into the pGEM7zf(+) vector available from Promega. Mnh1 is Mrp of S. aureus. pGEM7zf(+) also contains the ampicillin resistance gene.) By introducing pGEMmnh1 into the KNabc strain by a conventional method, the KNabc strain transformed with mnh1 was obtained as a test E. coli. This test E. coli was called KNabc / pGEMmnh1.

[0043] 3.Appliances and equipment ·96-well clear polystyrene plate (Greiner No. 650901) Biotek Powerwave XS plate reader -UV-Visible Spectrophotometer UV 1800 (Shimadzu Corporation) 15 mL polystyrene tube (AS ONE No. 34184015D)

[0044] 4. Experimental Procedure (1) Preparation of LBK medium (pH 7.5) and LBK+NaCl medium (pH 7.5) 10 g of Bacto Tryptone, 5 g of Bacto Yeast Extract, and 6 g of KCl were dissolved in 800 mL of MilliQ water. In the case of LBK+NaCl medium, NaCl was further added to a predetermined final concentration (e.g., 300 mM). The pH was adjusted to 7.5 with 4M KOH. The volume was adjusted to 1 L by adding MilliQ water. The obtained liquid medium was dispensed into pressure bottles in 200 mL portions and sterilized by autoclaving (121°C, 20 minutes).

[0045] (2)Culture (2-1) 2 mL of LBK medium (pH 7.5) supplemented with 2 μL each of 100 mg / mL ampicillin and kanamycin solutions was placed in a 15 mL culture tube, the KNabc / pGEMmnh1 strain was inoculated, and preculture was performed at 37°C for 7 to 8 hours with shaking at 200 rpm.

[0046] (2-2) The turbidity of the preculture solution was measured using a spectrophotometer, and the turbidity (OD 600 The preculture was inoculated into the main culture so that the β-actin ratio was 0.01. The main culture was prepared by adding the same antibiotics as above to LBK medium or LBK+NaCl medium.

[0047] (2-3) The inoculated culture medium was dispensed in 40 μL portions into a 96-well microplate in which different test compounds dissolved in DMSO solvent were placed in separate wells to provide test compound-containing samples (final test compound concentration: 50 μM). In the lanes at both ends of each microplate, multiple samples (n≧4) were provided, including "Control" samples in which the test compound was omitted from the test compound-containing samples, i.e., DMSO solvent was added instead of the DMSO solution of the test compound, and "Background" samples in which not only the test compound but also the test E. coli was omitted (Figure 3). Test compound-containing samples as well as "Control" and "Background" samples were provided for each of the LBK medium and LBK+NaCl medium.

[0048] (2-4) The microplate was placed in a Biotek Powerwave XS plate reader and cultured at 37°C for 17 hours with shaking at 570 r / min (main culture). OD was measured every 0.5 or 1 hour. 600 The experiment was carried out in an automatic mode to measure the turbidity of the medium, i.e., the growth rate of the test E. coli.

[0049] 5. Data Processing (1) Data quality control Based on the measured values ​​of the "Background" and "Control" samples, which were placed multiple times on each plate, the S / B, CV (Background), CV (Control), and Z' were calculated for each plate (n≧4). Where: S / B = MeanC / MeanB CV (%) = 100(SDB / MeanB) or 100(SDC / MeanC) ·Z' = 1-(3SDB+3SDC) / (MeanC-MeanB) where MeanB is the mean value of the Background, MeanC is the mean value of the Control, SDB is the standard deviation of the Background, and SDC is the standard deviation of the Control.

[0050] (2) Inhibition rate calculation The inhibition rate (%) was calculated by subtracting the background mean value from the measured value of the sample containing the test compound (A), dividing the result by the control mean value minus the background mean value (B), and multiplying the result by 100. That is, inhibition rate (%) = (A / B) × 100. The smaller the inhibition rate number, the more the growth of the test E. coli was reduced by the test compound, i.e., the greater the inhibition.

[0051] 6.Results The first sodium ion concentration was set to 0 mM (provided by LBK medium without NaCl) and the second sodium ion concentration was set to 300 mM (provided by LBK medium with 300 mM NaCl added). The OD 600 An example of the results of screening tests based on measurements is shown in Table 1.

[0052] [Table 1]

[0053] Non-coli Na + / H + Depending on the presence of antiporters, Na +When screening test compounds with resistance guaranteed, positive growth inhibition was observed quite frequently, which may make the screening method inefficient (see the third column of Table 1). However, most of the positive compounds were found to be inhibitory to non-E. coli Na + / H + Low Na content without antiporter activity + It was found that growth inhibition occurred even under certain concentration conditions, and it can be excluded from the list of candidates for the specific inhibitor of interest.

[0054] It was revealed that test compounds that allow practically normal growth at low sodium ion concentrations, such as test compounds 9, 16, and 20 in Table 1, but cause significant growth inhibition of the test E. coli at high sodium ion concentrations, could be clearly distinguished from a large number of test compounds and identified. Such a result was not necessarily expected. One of the characteristics of Mrp is the fact that the subunits presumed to be involved in ion transport have homology to NuoL, NuoM, and NuoN, which are proton transport subunits of complex I (NADH oxidoreductase) of the respiratory chain complex (Mathiesen & Hagerhall, BBA, 2002). NuoL, NuoM, and NuoN of complex I of the respiratory chain complex are also called "antiport subunits," and in 2013, Baradaran and Sazanov et al. analyzed the crystal structure to reveal their detailed H structure. + The transport pathway was revealed (Baradaran et al., Nature, 2013). MrpA, MrpD, NuoL, NuoM, and NuoN share a common NDH-I domain, and the charged amino acid residues predicted to be involved in ion transport are also highly conserved. and Mitochondria naturally contain respiratory chain complex I, but Mrp-type Na + / H + Compounds that inhibit ion transport of the antiporter are expected to have an inhibitory effect on respiratory chain complex I. Such inhibitors may be difficult to administer to humans. The results of this example show that Mrp-type Na + / H +This is the first example showing that selective inhibitors of an antiporter can exist and that such inhibitors can be clearly identified.

Claims

1. Non-coli Na + / H + A method for screening a specific inhibitor of an antiporter, comprising the steps of: (a-1) Endogenous Na + / H + The antiporter gene is deleted and the non-E. coli Na + / H + Cultivating a test E. coli strain into which an antiporter gene has been introduced in the presence of a test compound in a first sodium ion concentration range of less than 10 mM; (a-2) culturing the test E. coli in the presence of the test compound and under a second sodium ion concentration range of 50 to 500 mM; (a-3) culturing the test E. coli in the first sodium ion concentration range in the absence of the test compound; (a-4) culturing the test E. coli in the second sodium ion concentration range in the absence of the test compound; and (b) comparing the growth rate of the test E. coli in (a-1) with the growth rate of the test E. coli in (a-3), and comparing the growth rate of the test E. coli in (a-2) with the growth rate of the test E. coli in (a-4); and performing an assay comprising the steps of: for a plurality of test compounds, wherein, when there is no growth inhibition in the test E. coli in (a-1) compared to the growth of the test E. coli in (a-3), and there is growth inhibition in the test E. coli in (a-2) compared to the growth of the test E. coli in (a-4), the test compound is identified as a candidate for a specific inhibitor. method.

2. The non-E. coli Na + / H + Antiporter is Mrp type Na + / H + The method of claim 1, which is an antiporter.

3. 3. The method of claim 1 or 2, wherein the test E. coli is deficient in endogenous nhaA and nhaB genes.

4. The method according to any one of claims 1 to 3, wherein the culturing of (a-1) to (a-4) is carried out simultaneously for at least 40 types of test compounds.

Citation Information

Patent Citations

  • Na+ / H+ antiporter protein and gene coding for the same

    JP2000157287A

  • Na+ / H+ anti-porter gene, and improvement of base resistance by expression of the gene

    JP2003180373A

  • Method for discriminating proton pump inhibitor

    JP2010200680A

  • Method for measuring sodium-proton-exchange ligand efficiency

    JP2012503765A

  • Novel slc17-type transporter protein in mammal and use thereof

    WO2008126517A1